Forum Replies Created
-
Posts
-
I researched this one for about 3 months so happy to share what I found.
On titration: the gradual dose increase is primarily about GI tolerance. The most common side effects (nausea, reduced appetite to the point of discomfort) are dose-dependent and much more manageable when you ease in. The clinical trials all use titration protocols for this reason, starting at a therapeutic dose right away produces much higher rates of GI side effects.
On timeline: appetite changes tend to be noticeable fairly early (1-2 weeks in some cases) but the more meaningful changes in body composition research happen over 8-12+ weeks. The drug has a ~7-day half-life so it takes several weeks to reach steady state.
On stacking: in the research literature it’s often run solo, at least initially, to establish tolerability. Some researchers do combine it with compounds targeting different mechanisms (like a GHRH/GHRP stack) but I’d get comfortable with it on its own first.
Good question, I kept everything else as consistent as I could specifically because I wanted to isolate the variable. Same training volume, same diet. The timing of the improvement aligns closely enough with the protocol that I’m fairly confident it’s the primary driver.
Without DAC, I’ve seen that the DAC version has a much longer half-life which makes the pulsatile nature less predictable. Planning to do twice daily (morning fasted + pre-sleep) to start. Thanks for the clarification on fat + insulin, hadn’t considered dietary fat separately from carbs.
I’ve personally run BPC-157 subcutaneously for a knee issue and had solid results. Never tried oral so I can’t compare from experience, but Pete’s breakdown matches what I’ve read in the research summaries.
One practical note: subcutaneous injection near the site of injury seems to be a common protocol in the research literature for localized healing, worth factoring in depending on what you’re targeting.
